Here, researchers are developing a 14.3 kDa anti-CD8 VHH tracer (B), along with a nonbinding control tracer (C), in order to track CD8+ (“cytotoxic”) T cells in malignant tumors during immunotherapy by Positron Emission Tomography (PET).
We're back with another SCGE Spotlight! This month, we've got: - 2 recent publications - Links to our "Meet the Expert" webinar series recordings - Upcoming SCGE researcher presentations at ASGCT Breakthroughs